PRNewsWire
10 Dec 2025, 01:30 UTC · 40w ago
Verdict
Headline takes no side. We score 603501.SS +0.30 across three claims — moderately bullish.
+0.30moderately bullish
More positive than 58% of ticker scores this week
What the story claims
3 claims · scored −1 bearish … +1 bullish
D3 Bio completed a $108 million Series B financing round backed by investors including IDG Capital, SongQing Capital, Temasek, and WuXi AppTec's Corporate Venture Fund.
So whatSecuring significant late-stage private funding from reputable global institutional investors reduces bankruptcy risk and validates the company's valuation.
More positive than 91% of claims this week
The funding will be primarily used to launch a global Phase III pivotal program for lead asset elisrasib (D3S-001) targeting KRAS G12C-mutant cancers.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 2 movers · tap to explore
More positive than 84% of claims this week
D3 Bio intends to pursue global regulatory submissions for elisrasib across the United States, China, and the European Union.
More positive than 65% of claims this week
Which stocks this story touches
More positive than 58% of ticker scores this week
WuXi AppTec's corporate venture fund is an investor in D3 Bio's successful $108 million funding round.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
24/7 Wall Street
2h ago
—
No price for 603501.SS right now — the quote feed didn't answer.
603501.SS chart →
